Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...

Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its ...

“As a leader in cancer testing, we recognise the critical need to provide earlier answers and treatment guidance, with a bold mission to advance cancer care and, one day, turn cancer into a ...

No need for rose-tinted glasses here. Mission’s resurrected 770 offer an excellent alternative to the established class leaders Why you can trust What Hi-Fi? Our expert team reviews products in ...

The Royal Charter states that the BBC’s object is “the fulfilment of its Mission and the promotion of its Public Purposes” Our mission is "to act in the public interest, serving all ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Healthcare analytics company PurpleLab joined the Network Advertising Initiative. Biogen and Neomorph announced a multi-target research collaboration to discover and develop molecular glue degraders ...

Updates will continue to be posted here so be sure to check back regularly. While construction is ongoing, we ask and thank you for your ongoing patience as crews work hard to rehabilitate this ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...